| Gene symbol | MAGEA4 | Synonyms | CT1.4, MAGE-41, MAGE-X2, MAGE4, MAGE4A, MAGE4B | Type of gene | protein-coding |
| Chromosome | X | Map location | Xq28 | dbXrefs | |
| Description | MAGE family member A4 | ||||
| GTO ID | GTC2161 |
| Trial ID | NCT04044859 |
| Disease | Head and Neck Cancer | Urethra Cancer | Lung Non-Small Cell Carcinoma | Endometrial Cancer | Ovarian Cancer | Stomach Cancer | Esophageal Cancer | Melanoma |
| Altered gene | MAGE-A4 |
| Therapeutic/Target gene | Target gene |
| Therapy | TCR-T cell |
| Treatment | ADP-A2M4CD8 |
| HLA | HLA-A*02 |
| Phase | Phase1 |
| Recruitment status | Recruiting |
| Title | A Phase 1 Dose Escalation Study To Assess Safety And Efficacy Of ADP-A2M4CD8 As Monotherapy Or In Combination With Either Nivolumab Or Pembrolizumab In HLA-A2+ Subjects With MAGE-A4 Positive Tumors (SURPASS) |
| Year | 2019 |
| Country | United States |
| Company sponsor | Adaptimmune |
| Other ID(s) | ADP-0055-001 |
| Vector information | |||
|
|||
| Cohort 1 | |||||||||||
|
|||||||||||